# US 2006/0154966 A1 · Novel raloxifene acid additon salts and/or solvates thereof, improved method for purification of said raloxifene acid addition salts and/or solvates thereof and pharmaceutical compositions comprising these

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0154966 A1
- Document ID: US20060154966A1
- Status: Published application
- Kind: A1
- Application number: 10/528,691
- Filed: 2003-09-30
- Published: 2006-07-13
- Earliest claimed: 2002-09-30
- Assignees: A/S GEA Farmaceutisk Fabrik
- Inventors: Gunnar Karup; Soren Bols Pedersen
- Web page: https://patentgrep.com/patent/US20060154966A1

## CPC

- C07D 333/56: Radicals substituted by oxygen atoms
- A61P 19/00: Drugs for skeletal disorders
- A61P 35/00: Antineoplastic agents
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Raloxifene acid addition salts or solvates thereof, having improved dissolution properties in media comprising hydrochloric acid are described, compared with similar preparations based on raloxifene or raloxifene hydrochloride. The disclosed acid addition salts or solvates thereof show an improved bioavailability in media comprising hydrochloric acid, such as the gastric juice. The acid addition salts or solvates thereof are addition salts or solvates of raloxifene and a pharmaceutical acceptable acid selected among succinic acid, lactic acid, malonic acid or sulphuric acid. Further, crystalline forms of the raloxifene salts and solvates thereof are disclosed. The raloxifene acid addition salts and/or solvates thereof are useful for the preparation of pharmaceutical composition for oral administration capable of fast and reliable release of the active ingredients in the stomach of the patient, in particular for the treatment of cancer or osteoporosis, or for inhibiting cartilage degradation. A new method for preparation of raloxifene lactate is also disclosed.

## Claims

### Claim 1

Raloxifene acid addition salt or solvate thereof wherein the raloxifene acid addition salt of solvate thereof is selected among: raloxifene D-lactate, raloxifene L-lactate, Raloxifene DL-lactate, raloxifene D-lactate hemihydrate, raloxifene D-lactate ¼-hydrate, raloxifene L-lactate hemihydrate, raloxifene L-lactate ¼-hydrate, raloxifene DL-lactate hemihydrate and raloxifene DL-lactate ¼-hydrate.

### Claim 2 (depends on 1)

Raloxifene acid addition salt or solvate thereof according to claim 1, wherein the raloxifene acid addition salt or solvate thereof is raloxifene L-lactate hemihydrate being in crystalline form having the following X-ray crystalline positions:
XRD:
D
2Theta
I(rel)
I(abs)
FWHM
14.639874
6.0322
17.56
6122
0.1200
13.207421
6.6871
15.07
5254
0.1200
10.875932
8.1229
80.41
28029
0.1200
9.268456
9.5347
22.67
7903
0.1200
8.140638
10.8593
17.92
6247
0.1200
7.488503
11.8083
15.59
5433
0.1000
7.310331
12.0971
12.47
4347
0.0800
7.089508
12.4754
25.79
8991
0.1000
6.931874
12.7603
12.78
4454
0.0900
6.723932
13.1566
27.83
9701
0.1300
6.551458
13.5045
14.20
4949
0.0900
6.359432
13.9143
30.57
10656
0.1100
6.130010
14.4378
21.33
7435
0.1300
5.853018
15.1249
36.40
12687
0.1100
5.626204
15.7385
15.49
5401
0.1300
5.507643
16.0795
23.25
8106
0.1000
5.447238
16.2590
13.21
4606
0.0870
5.224449
16.9573
19.21
6697
0.1100
5.160516
17.1690
17.10
5961
0.0870
5.083475
17.4312
14.74
5137
0.1100
4.954247
17.8896
19.64
6848
0.1000
4.863750
18.2252
28.34
9879
0.0800
4.805168
18.4494
46.26
16125
0.0700
4.756883
18.6383
49.99
17425
0.0800
4.656926
19.0420
19.10
6659
0.1900
4.630194
19.1530
17.96
6260
0.0870
4.566015
19.4248
21.34
7438
0.1000
4.487514
19.7680
12.76
4447
0.1000
4.347753
20.4101
11.69
4074
0.1100
4.301465
20.6322
19.17
6682
0.0900
4.224555
21.0120
14.55
5072
0.0870
4.186561
21.2049
23.33
8134
0.1700
4.065767
21.8425
26.06
9084
0.1000
4.015560
22.1190
17.10
5929
0.1000
3.976949
22.3365
14.98
5223
0.0500
3.935785
22.5732
34.50
12028
0.1100
3.867038
22.9799
100.00
34859
0.1000
3.779481
23.5198
40.14
13991
0.0800
3.742319
23.7567
59.68
20805
0.1000
3.710418
23.9640
13.17
4591
0.0870
3.645564
24.3968
11.19
3902
0.0800
3.621808
24.5593
18.71
6524
0.1000
3.552536
25.0459
16.01
5581
0.1000
3.516088
25.3098
13.46
4691
0.0600
3.498357
25.4402
12.66
4413
0.0700
3.467075
25.6737
10.74
3745
0.0500
3.418947
26.0414
21.49
7491
0.1000
3.395298
26.2260
12.12
4225
0.0870
3.369948
26.4268
15.48
5369
0.0700
3.358554
26.5181
14.33
4995
0.0600
3.244985
27.4641
11.90
4149
0.0700
3.229427
27.5990
9.63
3356
0.0870
3.177657
28.0578
15.07
5253
0.1200
3.144884
28.3562
32.65
11381
0.1000
3.106130
28.7176
9.83
3425
0.0800
3.082970
28.9380
9.00
3138
0.0870
3.056106
29.1980
8.56
2984
0.0870
3.032184
29.4335
8.74
3048
0.1100
2.994539
29.8121
8.27
2884
0.0700
2.979114
29.9700
9.26
3229
0.0800
2.924922
30.5387
9.19
3203
0.1800
2.870290
31.1346
16.32
5689
0.1400
2.828902
31.6019
13.59
4737
0.1100
2.762611
32.3808
10.83
3775
0.1000

### Claim 3 (depends on 1)

Raloxifene acid addition salt or solvate thereof according to claim 1, wherein the raloxifene acid addition salt or solvate thereof is raloxifene L-lactate ¼-hydrate being in crystalline form having the following X-ray crystalline positions:
XRD:
D
2Theta
I(rel)
I(abs)
FWHM
14.079244
6.2726
45.93
16568
0.1300
9.974912
8.8580
32.43
11699
0.1100
9.526523
9.2758
71.31
25721
0.1200
8.215598
10.7600
47.82
17248
0.1100
7.246270
12.2045
80.04
28871
0.1100
7.065557
12.5178
16.17
5832
0.0700
6.878001
12.8606
22.74
8201
0.1200
6.283709
14.0828
66.27
23901
0.0800
6.194698
14.2862
53.98
19470
0.0984
5.859529
15.1080
11.17
4028
0.0984
5.744935
15.4112
16.16
5828
0.1200
5.312222
16.6751
18.02
6499
0.1200
5.046910
17.5585
34.26
12356
0.0900
4.978933
17.8001
54.66
19715
0.1000
4.918535
18.0205
17.40
6277
0.0984
4.746264
18.6804
26.77
9655
0.1000
4.712771
18.8143
46.35
16716
0.0900
4.569429
19.4101
57.60
20777
0.1000
4.455985
19.9093
53.60
19332
0.1200
4.345589
20.4204
12.70
4579
0.0900
4.268096
20.7952
86.33
31139
0.0900
4.106332
21.6241
20.17
7274
0.1100
4.042283
21.9710
22.73
8197
0.1200
3.944656
22.5218
23.46
8462
0.1000
3.913129
22.7056
100.00
36069
0.1100
3.831706
23.1947
15.49
5586
0.0900
3.777075
23.5350
69.72
25148
0.1400
3.735872
23.7983
14.85
5358
0.0984
3.667856
24.2463
11.94
4305
0.0900
3.639035
24.4413
13.87
5001
0.0800
3.589918
24.7809
9.38
3383
0.0984
3.545715
25.0949
23.58
8505
0.0800
3.505655
25.3864
33.63
12131
0.1100
3.442223
25.8622
22.60
8152
0.1100
3.411017
26.1030
10.82
3901
0.0984
3.371851
26.4117
44.16
5108
0.1000
3.280618
27.1600
15.23
5494
0.1100
3.251104
27.4114
14.23
5134
0.0800
3.232072
27.5760
19.25
6943
0.1100
3.153056
28.2812
12.42
4479
0.1900
3.143130
28.3724
12.29
4432
0.0984
3.081939
28.9479
17.16
6189
0.2200
3.040378
29.3524
9.73
3510
0.1300
2.990508
29.8532
15.29
5514
0.1400
2.929711
30.4876
11.37
4102
0.1200
2.892397
30.8906
18.91
6822
0.1200
2.856192
31.2922
8.91
3214
0.1100
2.818108
31.7261
14.79
5336
0.2500
2.765584
32.3450
15.86
5720
0.1300

### Claim 4 (depends on 1)

Raloxifene acid addition salt or solvate thereof according to claim 1, wherein the raloxifene acid addition salt or solvate thereof is raloxifene DL-lactate hemihydrate being in crystalline form having the following X-ray crystalline positions:
XRD:
D
2Theta
I(rel)
I(abs)
FWHM
13.595814
6.4959
28.40
12683
0.1400
10.855533
8.1382
16.15
7211
0.1200
9.849394
8.9711
32.17
14369
0.1000
9.534325
9.2682
66.95
29898
0.1300
8.150249
10.8465
45.20
20188
0.1300
7.240730
12.2138
63.53
28374
0.1400
6.769843
13.0670
18.42
8227
0.1500
6.272666
14.1077
75.67
33794
0.1900
5.818832
15.2143
13.28
5933
0.2000
5.657337
15.6513
18.07
8070
0.1300
5.505030
16.0872
10.51
4692
0.1000
5.261933
16.8357
17.48
7806
0.1400
5.089504
17.4104
16.14
7210
0.1000
5.001569
17.7189
41.94
18732
0.0900
4.958950
17.8725
29.16
13023
0.1148
4.797388
18.4795
19.39
8660
0.1100
4.669322
18.9910
49.20
21972
0.1400
4.574684
19.3876
63.21
28227
0.1000
4.533019
19.5676
44.94
20071
0.1148
4.440548
19.9792
32.70
14604
0.1200
4.301886
20.6301
100.00
44659
0.1500
4.155406
21.3657
78.00
34833
0.1600
4.059049
21.8797
27.53
12296
0.1800
3.960846
22.4285
25.59
11427
0.1000
3.907408
22.7393
83.48
37282
0.1200
3.865461
22.9894
16.46
7350
0.1148
3.828892
23.2120
17.46
7798
0.0900
3.773130
23.5599
50.71
22649
0.1200
3.716486
23.9243
23.06
10300
0.1300
3.652238
24.3515
15.79
7053
0.1800
3.584725
24.8174
12.91
5764
0.1500
3.486791
25.5261
30.45
13600
0.1200
3.439149
25.8858
22.21
9919
0.1300
3.396267
26.2184
17.86
7978
0.1100
3.370045
26.4261
12.48
5572
0.1148
3.329320
26.7553
9.21
4113
0.1100
3.292728
27.0582
11.81
5274
0.1000
3.278070
27.1815
11.25
5026
0.1148
3.218620
27.6935
21.24
9485
0.1900
3.167986
28.1452
13.80
6162
0.0900
3.143230
28.3715
30.33
13546
0.1000
3.095423
28.9191
14.02
6260
0.1200
3.024921
29.5058
11.56
5161
0.1400
3.007253
29.6831
13.40
5984
0.1300

### Claim 5

Raloxifene acid addition salt or solvate thereof being raloxifene succinate in crystalline form having the following X-ray crystallographic positions:
XRD:
D
2Theta
I(rel)
I(abs))
FWHM
13.195230
6.6933
20.78
8475
0.1400
9.695642
9.1137
13.43
5476
0.0300
9.304945
9.4972
18.19
7419
0.1300
8.394523
10.5300
13.26
5407
0.1000
7.944460
11.1283
14.15
5768
0.1000
7.708667
11.4699
17.61
7180
0.1200
7.526675
11.7482
12.32
5023
0.0898
7.323294
12.0756
15.22
6205
0.1000
7.160495
12.3512
13.04
5316
0.0800
6.926815
12.7696
23.68
9655
0.1300
6.606409
13.3917
29.08
11856
0.1400
6.463392
13.3894
14.45
5891
0.0898
6.285432
14.0789
21.24
8662
0.1200
6.127742
14.4432
63.63
25947
0.1200
5.961999
14.8469
15.55
6342
0.0900
5.875574
15.0665
15.77
6430
0.0898
5.788967
15.2933
16.15
6585
0.1400
5.624221
15.7441
34.74
14167
0.1200
5.453763
16.2394
22.89
9334
0.1300
5.276560
16.7887
12.71
5182
0.1200
5.095057
17.3913
14.19
5786
0.1100
5.020392
17.6520
11.12
4535
0.0898
4.835944
18.3309
18.30
7461
0.1200
4.765096
18.6059
18.62
7591
0.1100
4.630456
19.1519
65.88
26864
0.1600
4.525518
19.6003
15.16
6180
0.0800
4.484997
19.7792
24.48
9982
0.1000
4.376528
20.2745
18.78
7659
0.1000
4.352225
20.3889
19.11
7790
0.1000
4.227757
20.9959
29.39
11984
0.1000
4.191265
21.1808
56.82
23171
0.0800
4.158052
21.3520
40.16
16377
0.0898
4.101947
21.6475
17.14
6988
0.0800
4.062068
21.8626
19.79
8072
0.1000
4.010082
22.1496
11.70
4771
0.0600
3.921660
22.6556
100.00
40776
0.1300
3.860487
23.0194
29.04
11842
0.1100
3.813566
23.3066
19.25
7850
0.1100
3.732687
23.8189
19.33
7884
0.1300
3.694791
24.0669
22.47
9161
0.1100
3.644300
24.4054
18.84
7680
0.1400
3.544078
25.1067
13.63
5556
0.0700
3.496160
25.4565
16.28
6637
0.0898
3.446458
25.8299
20.36
8300
0.2100
3.398344
26.2021
12.35
5036
0.1200
3.373032
26.4022
8.82
3597
0.0898
3.305938
26.9481
14.08
5741
0.1100
3.281940
27.1489
10.08
4112
0.0898
3.260437
27.3314
9.66
3937
0.0898
3.227083
27.6194
19.22
7838
0.1200
3.179256
28.0434
16.28
6640
0.2600
3.146269
28.3435
8.89
3627
0.0898
3.121159
28.5764
9.58
3907
0.0900
3.097691
28.7975
10.64
4337
0.0400
3.074307
29.0213
19.64
8008
0.1200
3.032262
29.4328
10.17
4148
0.1300
3.010128
29.6541
9.43
3847
0.0898

### Claim 6

Raloxifene acid addition salt or solvate thereof being raloxifene sulphate 2-propanol solvate.

### Claim 7 (depends on 6)

Raloxifene acid addition salt or solvate thereof according to claim 6, wherein raloxifene sulphate 2-propanol solvate is in crystalline form having the following X-ray crystallographic positions:
XRD:
D
2Theta
I(rel)
I(abs)
FWHM
14.374007
6.1439
26.57
5009
0.0900
10.303750
8.5748
29.62
5583
0.1300
9.201529
9.6042
26.22
4942
0.1100
8.871726
9.9621
29.84
5624
0.1300
8.569965
10.3138
22.25
4195
0.0400
8.320378
10.6241
25.97
4896
0.1200
7.945119
11.1274
38.65
7286
0.1300
7.514174
11.7678
20.56
3876
0.1041
7.205108
12.2745
25.04
4721
0.1400
6.537437
13.5336
66.78
12590
0.1400
6.228787
14.2076
21.88
4126
0.1100
5.628329
15.7325
20.71
3904
0.0900
5.540447
15.9837
27.40
5166
0.1100
5.322476
16.5489
64.98
12249
0.1500
5.138694
17.2425
21.65
4082
0.1100
5.020317
17.6522
64.05
12074
0.1400
4.706881
18.8381
100.00
18851
0.1300
4.618097
19.2036
60.47
11400
0.0800
4.538129
19.5453
59.35
11189
0.1100
4.471816
19.8381
67.03
12636
0.1200
4.261964
20.8255
54.78
10327
0.1100
4.204757
21.1121
51.35
9680
0.1600
4.156029
21.3625
46.65
8794
0.1041
4.093305
21.6938
25.93
4888
0.0900
4.035960
22.0058
24.21
4563
0.1800
3.937182
22.5651
25.37
4784
0.1200
3.835400
23.1721
22.17
4179
0.0900
3.796528
23.4127
40.94
7718
0.0900
3.767170
23.5978
61.03
11505
0.1100
3.691303
24.0899
20.10
3790
0.1500
3.639317
24.4393
47.20
8897
0.1200
3.590489
24.7769
28.23
5321
0.1600
3.511060
25.3467
29.66
5592
0.1100
3.478586
25.5873
23.70
4468
0.1041
3.416539
26.0601
37.38
7047
0.1900
3.355389
26.5436
20.28
3823
0.1300
3.314637
26.8760
17.08
3220
0.1200
3.271015
27.2413
15.24
2874
0.0600
3.252583
27.3987
14.71
2773
0.1041
3.100446
28.7714
23.04
4344
0.1200
3.079703
28.9694
19.73
3720
0.1041
3.033828
29.4172
29.23
5511
0.1300
3.009744
29.6580
15.28
2880
0.1041
2.937725
30.4024
13.30
2507
0.1700

### Claim 8

Raloxifene acid addition salt or solvate thereof being raloxifene malonate in crystalline form having the following X-ray crystalline positions:
XRD:
D
2Theta
I(rel)
I(abs)
FWHM
14.385166
6.1391
36.51
6471
0.0100
13.125024
6.7292
38.91
6896
0.1300
10.305386
8.5734
37.32
6614
0.1700
9.279238
9.5236
39.85
7062
0.1300
8.860721
9.9745
34.60
6133
0.0900
8.510328
10.3863
33.27
5895
0.0900
8.314361
10.6318
33.02
5852
0.0800
7.947949
11.1234
41.61
7375
0.1600
7.265135
12.1727
35.79
6343
0.1300
6.882996
12.8512
29.65
5254
0.0300
6.537915
13.5326
60.19
10667
0.1800
6.258251
14.1404
61.12
10833
0.2100
6.003203
14.7444
31.92
5657
0.1200
5.877911
15.0605
29.17
5170
0.0600
5.794580
15.2784
29.33
5198
0.0200
5.663226
15.6349
49.63
8796
0.1300
5.550457
15.9547
36.61
6487
0.0800
5.354103
16.5438
55.84
9897
0.2200
5.134028
17.2583
30.18
5349
0.1378
5.023848
17.6397
55.21
9784
0.2100
4.836637
18.3283
36.13
6404
0.1400
4.700761
18.8628
71.64
12696
0.1600
4.644808
19.0922
86.46
15323
0.1500
4.538522
19.5436
61.36
10874
0.1300
4.472256
19.8361
50.40
8931
0.1000
4.347111
20.4132
37.86
6709
0.1000
4.247918
20.8951
88.12
15616
0.2300
4.161428
21.3344
73.93
13101
0.1600
4.085803
21.7341
37.19
6591
0.1100
4.019584
22.0966
35.60
6309
0.1500
3.921695
22.6554
100.00
17722
0.1700
3.765729
23.6059
50.70
8986
0.2000
3.703455
24.0097
34.79
6166
0.1200
3.638542
24.4446
47.30
8382
0.1900
3.499221
25.4339
44.29
7849
0.2000
3.426872
25.9801
43.63
7732
0.2200
3.292398
27.0610
23.39
4145
0.1000
3.253755
27.3886
25.03
4435
0.1400
3.192249
27.9269
22.18
3931
0.1400
3.094846
28.8246
28.68
5083
0.3000
3.034329
29.4123
27.30
4338
0.1900.

### Claim at position 9

9-10. (canceled)

### Claim 11 (depends on 1)

Pharmaceutical composition capable of fast and reliable release of the active ingredients in gastric juice, comprising a raloxifene acid addition salt or solvate thereof according to claim 1.

### Claim 12 (depends on 11)

Pharmaceutical composition according to claim 11, wherein the pharmaceutical is intended for the treatment of cancer or osteoporosis, or for inhibiting cartilage degradation.

### Claim 13

Process for the manufacture of raloxifene lactate comprising the following steps:
to a solution of the compound having the general formula I in an solvent
wherein R represents two independently selected hydroxyl protection groups,
a suitable reagent is added in order to remove the protection groups;
lactic acid is added to the mixture, and
raloxifene lactate is precipitated from the mixture and isolated.

### Claim 14 (depends on 13)

Process according to claim 13, wherein the groups R are independently selected from: C1-C4 alkyl, C5-C7 cycloalkyl, benzyl —COR2 or SO2R2, wherein R2 is C1-C4 primary or secondary alkyl, C1-C3 fluoroalkyl, C1-C3 chloroalkyl, C1-C4 alkylphenyl, C1-C4 alkoxyphenyl, mono- or dinitrophenyl or mono- or di(chloro or fluoro)phenyl.

### Claim 15 (depends on 13)

Process according to claim 13, wherein the two R groups are identical.

### Claim 16 (depends on 13)

Process according to the claim 13, wherein the solvent is selected from alcohols having 1 to 5 carbon atoms.

### Claim 17 (depends on 16)

Process according to claim 16, wherein the alcohol is a monovalent alcohol.

### Claim 18 (depends on 17)

Process according to claim 17, wherein the alcohol is ethanol.

### Claim 19 (depends on 18)

Process according to claim 18, wherein the alcohol is 96% ethanol.

### Claim 20 (depends on 13)

Process according to claim 13, wherein the lactate is L-lactate.
